Literature DB >> 24599432

Voriconazole-induced periostitis in a patient with overlap syndromes.

Keisho Hirota1, Akihiro Yasoda, Toshihito Fujii, Nobuya Inagaki.   

Abstract

A 52-year-old woman with overlap syndrome and interstitial pneumonia underwent immunosuppressive therapy and she was suspected to suffer from pulmonary aspergillosis. Oral voriconazole was initiated, and a rapid elevation of alkaline phosphatase (ALP) occurred after 4 weeks. After 2 months, the patient presented diffuse pain in bilateral skeletal regions, and bone scintigraphy revealed bilateral multiple areas of increased radiotracer uptake. We suspected the skeletal involvement as voriconazole-induced periostitis. Actually, the plasma fluoride level was increased. Voriconazole was replaced with itraconazole, and after 3 weeks, the patient stopped complaining of bone pain concomitant with the decrease in ALP. Voriconazole-induced periostitis is a rare condition but had previously been reported in solid organ or patients with bone marrow transplant who received a long-term voriconazole therapy. Our present case is distinctive of previous ones, because it occurred in a patient with connective tissue disease which had its rapid progression.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24599432      PMCID: PMC3948152          DOI: 10.1136/bcr-2013-203485

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  18 in total

1.  Fluorosis because of prolonged voriconazole therapy in a teenager with acute myelogenous leukemia.

Authors:  Jodi L Skiles; Erik A Imel; John C Christenson; Jennifer E Bell; Monica L Hulbert
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

2.  A case of periostitis secondary to voriconazole therapy in a heart transplant recipient.

Authors:  Steven M Wise; Michael A Wilson
Journal:  Clin Nucl Med       Date:  2011-03       Impact factor: 7.794

3.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

4.  Voriconazole-induced periostitis.

Authors:  Christine Rossier; Vincent Dunet; Frederic Tissot; Berengère Aubry-Rozier; Oscar Marchetti; Olivier Marchetti; Ariane Boubaker
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-06       Impact factor: 9.236

5.  Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy.

Authors:  Robert A Wermers; Kay Cooper; Raymund R Razonable; Paul J Deziel; Gary M Whitford; Walter K Kremers; Thomas P Moyer
Journal:  Clin Infect Dis       Date:  2011-01-16       Impact factor: 9.079

Review 6.  Medication-induced periostitis in lung transplant patients: periostitis deformans revisited.

Authors:  Lina Chen; Michael E Mulligan
Journal:  Skeletal Radiol       Date:  2010-07-22       Impact factor: 2.199

7.  Serum ionic fluoride concentrations are related to renal function and menopause status but not to age in a Japanese general population.

Authors:  Kazuyoshi Itai; Toshiyuki Onoda; Masaru Nohara; Masaki Ohsawa; Kozo Tanno; Tamotsu Sato; Toru Kuribayashi; Akira Okayama
Journal:  Clin Chim Acta       Date:  2009-11-24       Impact factor: 3.786

8.  Periostitis secondary to prolonged voriconazole therapy in lung transplant recipients.

Authors:  T F Wang; T Wang; R Altman; P Eshaghian; J P Lynch; D J Ross; J A Belperio; S S Weigt; R Saggar; A Gregson; B Kubak; R Saggar
Journal:  Am J Transplant       Date:  2009-10-21       Impact factor: 8.086

9.  Pretreatment with low doses of norethindrone potentiates the osteogenic effects of fluoride on human osteosarcoma cells.

Authors:  J Takada; D J Baylink; K H Lau
Journal:  J Bone Miner Res       Date:  1995-10       Impact factor: 6.741

10.  Reversible skeletal disease and high fluoride serum levels in hematologic patients receiving voriconazole.

Authors:  Bernhard Gerber; Roman Guggenberger; David Fasler; Gayathri Nair; Markus G Manz; Georg Stussi; Urs Schanz
Journal:  Blood       Date:  2012-08-02       Impact factor: 22.113

View more
  5 in total

1.  Voriconazole-related periostitis presenting on magnetic resonance imaging.

Authors:  Derik L Davis
Journal:  Clin Cases Miner Bone Metab       Date:  2015 Jan-Apr

2.  Voriconazole-induced periostitis deformans: serial imaging in a patient with ANCA vasculitis.

Authors:  S Cormican; N Adams; P O'Connell; A McErlean; D de Freitas
Journal:  Skeletal Radiol       Date:  2017-09-02       Impact factor: 2.199

Review 3.  Voriconazole-induced periostitis: a new rheumatic disorder.

Authors:  Marwan H Adwan
Journal:  Clin Rheumatol       Date:  2016-07-04       Impact factor: 2.980

4.  Voriconazole-Induced Periostitis & Enthesopathy in Solid Organ Transplant Patients: Case Reports.

Authors:  Monica Sircar; Camille Kotton; David Wojciechowski; Kassem Safa; Hannah Gilligan; Eliot Heher; Winfred Williams; Ravi Thadhani; Nina Tolkoff-Rubin
Journal:  J Biosci Med (Irvine)       Date:  2016-11-10

5.  Diffuse periostitis as the primary presenting radiological finding in an AML patient with disease relapse.

Authors:  Raza Mushtaq; David Nolte; Faryal Shareef; Mihra S Taljanovic
Journal:  Radiol Case Rep       Date:  2018-08-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.